Xbrane Biopharma’s efforts to divest the subsidiary Primm Pharma continues although negotiations with the previously expected acquirer NewFaDem for the time being has been paused.
Primm Pharma is a fully owned subsidiary of Xbrane specialized in long-acting injectables and developer of Spherotide, a long-acting triptorelin formulation candidate intended to be used in treatment of prostate cancer, breast cancer, endometriosis and myoma. Primm Pharma has out-licensed IP and production equipment related to Spherotide to ICI S.r.l, located in Italy. Primm Pharma has during 2021 generated limited royalties from this license and is expected to generate further royalties during 2022 and onwards. At the same time costs in Primm Pharma has been eliminated, resulting in the subsidiary reaching cash-flow positive stage from fourth quarter of 2021 and onwards, states Xbrane.
The efforts continue
“Negotiations with the previously expected acquirer NewFadem with whom a non-binding term sheet was signed in February 2021, have been paused due to inability to reach a final agreement.”
The efforts in divesting Primm Pharma continues as Xbrane wants to focus on the development and sale of biosimilars. However, negotiations with the previously expected acquirer NewFadem with whom a non-binding term sheet was signed in February 2021, have been paused due to inability to reach a final agreement. Therefore, Xbrane now continues the efforts to divest Primm Pharma with other potential acquirers.
Photo of Martin Åmark, CEO, Xbrane